Veru Reports that Independent Data Monitoring Committee for the Phase 3 Sabizabulin COVID-19 Clinical Study Recommends Continuing Study as Planned
--Planned Conditional Statistical Power Analysis was Conducted— --Primary Efficacy Study Endpoint Is Proportion of Patients that Die on Study Up...